Future work may investigate the reason for aberrant alteration in CLSTN1 in FXS, determine the factors that regulate CLSTN1 to initiate ICAM5 transportation, and provide mechanistic insights into how dysfunctional CLSTN1 signaling pathway contributes to neurodevelopmental disorders. This evidence concerns the gene CLSTN1 and fragile X syndrome.